The company would be able to raise funds at a lower cost of interest and would be able to disburse up to 40% of its own fund to the borrowe...

We will see the bottom line and top line improving for the company. Investor should stay invested in this stock.

We are seeing very strong loan growth for this company.

Being one of the leading companies in pharmaceutical space, investors should stay invested in this stock.

There is plenty of supply coming in the near future in cement.

It is becoming one of the largest tower company with 85,000 towers post the merger of Reliance Infratel business with GTL Infra.

ET Now spoke to Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, for a fundamental check on JP Associates.

ET Now spoke to Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd., for a fundamental check on JSW Steel.

In an exclusive interview with ET Now, Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, talks about Astrazeneca.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd. in a chat with ET Now talks about RNRL.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, spoke to ET Now on markets.

ET Now Fundamental check with Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd.

ET Now Fundamental check with Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about markets.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about Nifty.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about Hindustan Unilever.

Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, in a chat with ET Now talks about Archies.